NASDAQ: BTTX - Better Therapeutics, Inc.

Rentabilité sur six mois: -99.12%
Secteur: Healthcare

Calendrier des promotions Better Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions.

plus de détails
In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

EBITDA -0.0057
EV/EBITDA -0.7443
IPO date 2021-10-28
ISIN US08773T1043
Industry Biotechnology
P/BV 3.35
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 1.8E-5
Сайт https://www.bettertx.com
Цена ао 0.0137
Число акций ао 0.02356 млрд
Changement de prix par jour: 0% (0.0001)
Changement de prix par semaine: 0% (0.0001)
Changement de prix par mois: 0% (0.0001)
Changement de prix sur 3 mois: 0% (0.0001)
Changement de prix sur six mois: -99.12% (0.0113)
Changement de prix par an: -99.95% (0.195)
Evolution du prix sur 3 ans: -100% (4.65)
Evolution du prix sur 5 ans: 0% (0.0001)
Evolution des prix sur 10 ans: 0% (0.0001)
Evolution des prix depuis le début de l'année: 0% (0.0001)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV -35.64 0
P/E 0 0
EV/EBITDA -0.8149 0
Total: 2.5

Efficacité

Nom Signification Grade
ROA, % -107.6 0
ROE, % -221.99 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.389 10
Total: 9.8

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 523.39 10
Rentabilité EPS, % 217.59 10
Total: 8
Plus de détails

Établissements Volume Partager, %
MMCAP International, Inc. SPC 356270 0.71
Citadel Advisors Llc 216165 0.43
Vanguard Group Inc 198154 0.4
Geode Capital Management, LLC 168821 0.34
Millennium Management LLC 128749 0.26
Blackrock Inc. 88635 0.18
Capital Investment Advisory Services, LLC 71000 0.14
State Street Corporation 58600 0.12
Susquehanna International Group, LLP 38057 0.08
Corient Private Wealth LLC 29180 0.06



Superviseur Titre d'emploi Paiement Année de naissance
Mr. David P. Perry M.B.A. Co-Founder & Executive Chairman 260k 1968 (57 années)
Mr. Frank L. Karbe CEO, Interim CFO, President & Director 533.37k 1968 (57 années)
Dr. Mark A. Berman M.D. Chief Medical Officer 573.75k 1976 (49 années)
Ms. Kristin Wynholds Chief Product Officer 519.07k 1973 (52 année)
Mr. Andres Camacho Senior VP of Technology & Head of Engineering N/A
Ms. Angela Willis Senior Vice President of Market Access N/A
Leslie Miller Controller N/A
Ms. Jessica Meng Chief Commercial Officer N/A

Adresse: United States, San Francisco. CA, 548 Market Street - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.bettertx.com